Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer

Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer

Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading...

Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Keymed Biosciences Announces 2025 Annual Results and Business Updates

BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization. Revenue Leaps Forward,...

Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation

Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 19, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in...

The 15th Five-Year Plan featuring opening up: China and the world sharing the future

The 15th Five-Year Plan featuring opening up: China and the world sharing the future

BEIJING, March 7, 2026 /PRNewswire/ -- A news report from China.org.cn on China's new efforts on further opening up: The 15th Five-Year Plan featuring opening up: China and the world sharing the future The year 2026 marks the beginning of China's...

Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results

Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology...

NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer

NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer

NEW YORK, Feb. 3, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content...

NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Begin Trading on NYSE in Record Transfer

NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Begin Trading on NYSE in Record Transfer

NEW YORK, Feb. 2, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content...

Lynx Analytics Introduces Lumen, an Agentic AI Framework to Improve Decision-Making in Life Sciences

Lynx Analytics Introduces Lumen, an Agentic AI Framework to Improve Decision-Making in Life Sciences

LOS GATOS, Calif., Jan. 14, 2026 /PRNewswire/ -- Lynx Analytics today announced Lumen, a specialized Agentic AI framework designed to help pharmaceutical and biotech organizations generate strategic, decision-ready insights from complex scientific...

Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy

Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy

TAIPEI and SAN DIEGO, Dec. 29, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of...

  • 1
  • 2
  • 3
  • menu
    menu